Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2] Core Views - The company reported a significant increase in revenue, achieving 303 million yuan in the first half of 2024, a year-on-year growth of 1071.20%. Excluding the impact of estimated returns of COVID-19 vaccines from the previous year, the revenue growth is 15.36% [6] - The net profit attributable to the parent company narrowed by 73.22% to -225 million yuan in the same period, indicating improved operational efficiency and cost control [6] - The sales revenue from the company's two types of meningococcal vaccines reached approximately 260 million yuan, a growth of about 18% year-on-year, with ongoing clinical trials for expanding age indications [6] - The company is progressing well in its pipeline development, with several products at various clinical trial stages, including PCV13i and DTcP vaccines [6] Summary by Sections Financial Performance - In the first half of 2024, the company achieved a revenue of 303 million yuan, with a year-on-year increase of 1071.20%. The net profit loss narrowed to -225 million yuan, a reduction of 73.22% [6] - For Q2 2024, the revenue was 189 million yuan, reflecting a year-on-year growth of 353.40%, with a net profit loss of -55 million yuan, a 92.12% reduction in loss compared to the previous year [6] Cost Management - The company has improved its cost management, with sales expenses decreasing by 12.70% year-on-year to 112 million yuan, and the sales expense ratio at 37.07% [6] - Management expenses were reduced by 38.45% year-on-year to 84 million yuan, with a management expense ratio of 27.52% [6] - R&D expenses decreased by 45.06% year-on-year to 186 million yuan, with an R&D expense ratio of 61.27% [6] Product Sales and Market Expansion - The sales revenue from meningococcal vaccines grew by 18% year-on-year, with ongoing market introduction efforts [6] - The company is conducting clinical trials for expanding the age indication for MCV4 vaccines, which could significantly increase market potential if approved [6] Pipeline Development - As of the first half of 2024, the company has several products in various stages of clinical trials, including PCV13i, DTcP, and Tdcp vaccines [6] - The company has received acceptance for the market application of PCV13i and is progressing with other vaccine candidates [6] Earnings Forecast and Valuation - The company is expected to generate revenues of 840 million yuan, 1.16 billion yuan, and 1.98 billion yuan for 2024, 2025, and 2026, respectively, with corresponding year-on-year growth rates of 135%, 38%, and 70% [7] - The estimated reasonable value range for the company's stock is between 59.85 and 68.68 yuan per share, corresponding to a market capitalization of 14.81 billion to 16.99 billion yuan [7]

Financial Performance - Revenue for the first half of 2024 reached RMB 285,420 thousand, a significant increase of 1,253.6% compared to RMB 21,086 thousand in the same period of 2023[8]. - Operating loss improved to RMB (250,466) thousand, a reduction of 81.3% from RMB (1,342,432) thousand year-over-year[8]. - The company reported a net loss of RMB (229,666) thousand for the period, an improvement of 82.1% from RMB (1,282,024) thousand in the same period last year[8]. - Basic and diluted loss per share improved to RMB (0.91) from RMB (3.41) year-over-year, reflecting a 73.3% reduction in loss per share[8]. - Gross profit for the six months ended June 30, 2024, was approximately RMB 187.2 million, a recovery from a gross loss of RMB 776.5 million in the same period last year, attributed to reduced inventory write-downs related to COVID-19 vaccines[52]. - The company incurred a net loss of RMB 225,373 thousand for the six months ended June 30, 2024, compared to a net loss of RMB 841,429 thousand for the same period in 2023[128]. - The group reported a total other income of RMB 54,127 thousand for the six months ended June 30, 2024, a decrease of 42% compared to RMB 93,946 thousand for the same period in 2023[147]. - The group incurred a loss of RMB 272,797 thousand for the six months ended June 30, 2024, down from RMB 396,127 thousand in the same period of 2023, indicating a reduction in losses by approximately 31%[148]. Assets and Liabilities - Total assets decreased by 12.7% to RMB 8,134,571 thousand from RMB 9,318,769 thousand as of December 31, 2023[8]. - Non-current assets declined by 13.1% to RMB 3,596,135 thousand compared to RMB 4,137,941 thousand at the end of 2023[8]. - Current liabilities were reduced by 26.4% to RMB 1,907,497 thousand from RMB 2,591,844 thousand in the previous period[8]. - Total liabilities decreased to RMB 3,075,025 thousand as of June 30, 2024, down from RMB 4,031,354 thousand as of December 31, 2023, reflecting a reduction of 23.7%[127]. - The company’s borrowings as of June 30, 2024, were RMB 1,184,976 thousand, a decrease from RMB 1,394,865 thousand as of December 31, 2023[127]. - Accounts payable decreased from approximately RMB 104.0 million as of December 31, 2023, to approximately RMB 77.8 million as of June 30, 2024, in line with reduced purchase volumes[70]. - Other payables and accrued expenses decreased by 35.6% to approximately RMB 553.2 million as of June 30, 2024, from approximately RMB 858.3 million as of December 31, 2023[73]. Research and Development - The company aims to continue developing high-quality, innovative, and affordable vaccines, leveraging the expertise of its senior management team[10]. - The company is advancing multiple vaccine candidates in clinical trials, including mRNA COVID-19 vaccines and a tuberculosis booster vaccine[11]. - The company’s R&D expenses for the period were RMB 185,902,000, down from RMB 338,372,000 in 2023, indicating a reduction of about 45%[125]. - The company aims to meet the high demand for innovative vaccines in China, leveraging advanced synthetic vaccine technology and improved formulation techniques[15]. - The company has established a comprehensive commercial operation center to execute marketing strategies for its products, including MCV4 vaccines[16]. Market and Product Development - The vaccine product line targets a large and underserved global market, categorized into three types: global innovative vaccines, first-in-class vaccines in China, and preclinical candidate vaccines[11]. - The company has five commercialized products addressing over ten disease areas, with sales revenue from the meningococcal vaccines reaching approximately RMB 262.7 million, an 18.0% increase year-over-year[17]. - The company has received conditional marketing approval for the recombinant COVID-19 vaccine, Kweisha®, in China and several other countries, with emergency use authorization granted for Kweisha® Mist and the XBB.1.5 variant vaccine[19]. - The company plans to submit an age expansion application for the MCV4 vaccine for children aged 4 to 6 years in 2024, having completed subject enrollment for clinical trials[17]. - The company is actively pursuing market expansion and product development strategies to enhance its competitive position in the vaccine market[109]. Corporate Governance and Shareholder Information - The company has adopted a corporate governance code and believes it has complied with all applicable provisions during the reporting period, except for the separation of the roles of Chairman and CEO, which are held by Dr. Yu[89]. - The company does not recommend the payment of an interim dividend for the reporting period, consistent with the previous year[97]. - The Audit Committee, composed of three independent non-executive directors, has reviewed the interim financial results and found them compliant with applicable accounting standards and regulations[95]. - The company has undergone changes in its board of directors, with new appointments and resignations effective February 21, 2024, including the election of Mr. Zhang as an independent non-executive director[90]. - As of June 30, 2024, Dr. Yu holds 34,598,400 H-shares (13.98%) and 42,579,625 A-shares (17.21%), representing significant ownership stakes in the company[98]. Cash Flow and Investments - Cash used in operating activities for the six months ended June 30, 2024, was RMB 250,946 thousand, significantly improved from RMB 790,142 thousand in the prior year[130]. - The company invested RMB 5,432,000 thousand in structured deposits and financial products during the first half of 2024, compared to RMB 2,815,000 thousand in the same period of 2023[130]. - The company plans to invest approximately RMB 2,244.7 million in the innovative vaccine industrial park project to enhance manufacturing capabilities, with RMB 718.9 million already invested[80]. - The company has not reported any significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures during the reporting period[79]. - The company’s cash and cash equivalents, including financial assets at fair value, totaled RMB 1,548,903,000 as of June 30, 2024, compared to RMB 1,309,570,000 at the end of 2023, indicating an increase of 18.3%[180].

证券代码：688185 证券简称：康希诺 公告编号：2024-044 康希诺生物股份公司 关于参加 2024 年半年度制药及生物制品专场 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 说明会召开时间：2024年9月18日（星期三）14:00-16:00 （二）会议召开地点：上证路演中心 说 明 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 说明会议召开方式：网络文字互动 投资者可于2024年9月17日（星期二）16:00前将需要了解和关注的问题发 送至康希诺生物股份公司（以下简称"公司"）邮箱ir@cansinotech.com，公司将在 说明会上对投资者普遍关注的问题进行回答。 公司于 2024 年 8 月 30 日发布 2024 年半年度报告，为便于广大投资者更全 面深入地了解公司 2024 年半年度经营成果、财务状况，公司参与了由上海证券 交易所主办的 2024 年半年 ...

编号：2024-008 证券代码：688185 证券简称：康希诺 康希诺生物股份公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------|----------------------------|----------------|------------------------------------------------------------| | | | | | | | □ 特定对象调研 □分析师会议 | | | | 投资者关系 | □ 媒体采访 □业绩说明会 | | | | 活动类别 | □ 新闻发布会 | □路演活动 | | | | □ 现场参观 | | √其他（业绩交流会、 | | | Amundi 、 | Ariose Capital | 、 | | 参与单位名 | Franklin 、 | | Fidelity、Manulife、Millennium、New Silk Road、Point | | 称及人员姓 | 72 | | 、淡水泉、东方资管、国源信达、海富通基金、鲸域资产、人保资 | | 名 | | | 管、上海混沌投资、上海泾溪投资、 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年8月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- ...

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of RMB 285,420,000, a significant increase of 1,253.6% compared to RMB 21,086,000 in the same period of 2023[11]. - The operating loss for the same period was RMB (250,466,000), representing an improvement of 81.3% from a loss of RMB (1,342,432,000) in 2023[11]. - The total comprehensive loss for the period was RMB (229,666,000), a reduction of 82.1% compared to RMB (1,282,024,000) in the previous year[11]. - Basic and diluted loss per share improved to RMB (0.91) from RMB (3.41), reflecting a 73.3% decrease in loss per share[11]. - Gross profit for the six months ended June 30, 2024, was approximately RMB 187.2 million, a recovery from a gross loss of RMB 776.5 million in the same period last year, attributed to reduced inventory write-downs and improved sales of meningococcal vaccines[55]. - The company reported a net loss of RMB 230,160,000 for the six months ended June 30, 2024, compared to a net loss of RMB 1,282,171,000 in the prior year, marking a reduction of approximately 82%[128]. - The company incurred a total comprehensive expense of RMB (224,879,000) for the six months ended June 30, 2024, compared to RMB (841,282,000) for the same period in 2023, reflecting a decrease of approximately 73%[131]. Assets and Liabilities - As of June 30, 2024, total assets decreased by 12.7% to RMB 8,134,571,000 from RMB 9,318,769,000 at the end of 2023[11]. - Non-current assets decreased by 13.1% to RMB 3,596,135,000 compared to RMB 4,137,941,000 at the end of 2023[11]. - Total liabilities decreased by 23.7% to RMB 3,075,025,000 from RMB 4,031,354,000 at the end of 2023[11]. - Current liabilities saw a significant reduction of 26.4%, down to RMB 1,907,497,000 from RMB 2,591,844,000[11]. - Cash and cash equivalents as of June 30, 2024, were RMB 1,722,218,000, down from RMB 2,046,998,000 at the end of 2023, representing a decrease of about 16%[129]. - The company’s borrowings decreased to RMB 990,929,000 as of June 30, 2024, from RMB 1,065,660,000 at the end of 2023, a reduction of about 7%[130]. Research and Development - The company aims to develop and commercialize high-quality, innovative, and affordable vaccines, supported by a team of top scientists and experienced professionals in the vaccine industry[13]. - The pipeline includes various innovative vaccines, such as mRNA COVID-19 vaccines and a recombinant tuberculosis booster vaccine, indicating ongoing research and development efforts[14]. - R&D expenses decreased by 45.1% to approximately RMB 185.9 million, as the focus shifted towards non-COVID-19 areas with several candidates nearing commercialization[60]. - The company is developing a globally innovative tuberculosis booster vaccine, which has shown good safety and tolerability in Phase Ia clinical trials, enhancing immunity in BCG-vaccinated individuals[36]. - The company plans to invest approximately RMB 2,244.7 million in the innovative vaccine industrial park project to enhance manufacturing capabilities, with RMB 718.9 million already invested[83]. Vaccine Products and Market Strategy - The vaccine product line targets a large and underserved global market, categorized into three types: global innovative vaccines, first-in-class vaccines in China, and preclinical candidate vaccines[14]. - The company has five commercialized products addressing over ten disease areas, with sales revenue from meningococcal vaccines reaching approximately RMB 262.7 million, an 18.0% increase year-over-year[20]. - The company has received conditional marketing approval for the recombinant COVID-19 vaccine, Kweisha®, in China and several overseas countries, with emergency use authorization granted for Kweisha® Mist and the XBB.1.5 variant vaccine[22]. - The company aims to meet the unmet medical needs in China with its high-quality vaccines, enhancing the overall healthcare landscape[18]. - The company has established a comprehensive commercial operation center to execute marketing strategies for Mankai Xin® domestically and internationally[19]. Shareholder and Corporate Governance - The company has adopted a corporate governance code to enhance shareholder rights and corporate value, ensuring transparency and accountability[22]. - The audit committee, consisting of three independent non-executive directors, reviewed the interim financial results and confirmed compliance with applicable accounting standards[98]. - The company has undergone changes in its board of directors, with new appointments and resignations effective February 21, 2024[93]. - The company has maintained compliance with the securities trading standards throughout the reporting period[97]. - The board believes that the current structure of having the chairman and CEO as the same individual does not affect the balance of power within the board[22]. Future Outlook and Strategic Initiatives - Future strategies include exploring global partnerships for vaccine development and considering acquisitions of promising assets related to vaccines and bioproducts to strengthen international market competitiveness[51]. - The company aims to enhance its marketing efforts and public awareness of vaccines, while also expanding its commercialization team to improve market penetration and cost management[50]. - The company plans to submit an age expansion application for the MCV4 vaccine for children aged 4 to 6 years in 2024, having completed subject enrollment for clinical trials[20]. - The company expects to obtain new drug marketing approval for PCV13i by 2025, following positive results from its Phase III clinical trial[27]. - The company has signed a funding agreement with the Bill & Melinda Gates Foundation in October 2023, securing over $2 million to support the development of the recombinant poliovirus vaccine[40].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2024, representing a 15% increase compared to the same period last year[1]. - The company's revenue for the first half of 2024 reached ¥303,431,446.47, a significant increase of 1,071.20% compared to ¥25,907,807.50 in the same period last year[15]. - The company achieved a revenue of approximately 262.72 million CNY from the sales of its meningococcal vaccine, an 18.00% increase from 222.65 million CNY in the previous year[18]. - The total revenue for the reporting period increased by 15.36% compared to the previous year, excluding the impact of COVID-19 vaccine returns[18]. - The company reported a total operating revenue for the first half of 2024 reached ¥303,431,446.47, a significant increase from ¥25,907,807.50 in the same period of 2023, reflecting a growth of approximately 1,067%[149]. - The company achieved a gross profit margin of approximately 74.7% in the first half of 2024, compared to 27.5% in the same period of 2023, indicating improved profitability[152]. - The net profit attributable to shareholders was -¥225,373,885.84, improving from -¥841,429,076.81 year-on-year[15]. - The net loss attributable to shareholders of the parent company was 225.37 million CNY, a significant reduction of 616.06 million CNY compared to the previous year[18]. - The company reported a significant increase in revenue for the first half of 2024, achieving a total of $500 million, representing a 25% growth year-over-year[104]. - The company expects a revenue growth of 10% for the second half of 2024, driven by new product launches and market expansion strategies[1]. Research and Development - Research and development expenses increased by 25% to RMB 300 million, focusing on new vaccine technologies[1]. - The company reported a total R&D investment of approximately ¥248.34 million, a decrease of 26.85% compared to the previous year, with R&D expenses accounting for 81.85% of operating income[51]. - Research and development expenses decreased to approximately ¥139.53 million from ¥275.04 million year-over-year, a reduction of about 49%[152]. - The company is committed to increasing R&D investment to accelerate product pipeline development and build a talent team[26]. - The company has developed innovative vaccines, including the inhaled COVID-19 vaccine, which has received emergency use authorization[22]. - The company has established five major technology platforms for vaccine development, enhancing its competitive product portfolio[44]. - The company has developed advanced vaccine technologies, including viral vector vaccines, synthetic vaccines, and mRNA vaccines, enhancing its R&D capabilities[43][47]. - The company is focusing on self-research and external collaborations to enhance its vaccine pipeline and competitiveness[26]. - The company is actively promoting its meningococcal vaccine products and expanding its CDMO business[18]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by the end of 2025[1]. - A strategic partnership was announced with a leading pharmaceutical company to enhance distribution channels, expected to improve logistics efficiency by 15%[1]. - The company is exploring acquisition opportunities in the biotech sector to diversify its product portfolio[1]. - The company is expanding its international presence with a focus on Southeast Asia, the Middle East, North Africa, and South America for its quadrivalent meningococcal vaccine[67]. - The company is considering strategic acquisitions to bolster its product offerings, with a budget of $200 million allocated for potential deals[106]. - The company is preparing for WHO PQ certification to explore the feasibility of international organization procurement for its innovative products[67]. - The company has established a comprehensive commercial operation center to expand its marketing network and improve product reputation[30]. Financial Position and Assets - The total assets decreased by 12.71% to ¥8,134,571,015.15 from ¥9,318,769,372.66 at the end of the previous year[15]. - The total assets at the end of the reporting period were ¥8,163,973,413.87, with overseas assets accounting for 5.33% of total assets[78]. - The company's total liabilities decreased by 31.33% to ¥462,528,796.20, mainly due to the exclusion of Shangyao Kangxino from the group's consolidated scope[77]. - The company's total comprehensive income for the period was ¥319,434.35, reflecting a significant change due to foreign currency translation differences[78]. - The company's total equity attributable to shareholders decreased from ¥5,274,604,094.18 to ¥5,059,547,135.34, a decline of about 4.1%[145]. - The company's cash and cash equivalents were reported at CNY 1.99 billion, down from CNY 2.82 billion, reflecting a decline of 29.3%[143]. - The company's long-term equity investments decreased to CNY 17.36 million, down by 4.4% from CNY 18.17 million[143]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faces risks related to competition, financial performance, and regulatory changes in the vaccine industry[71]. - The company is facing a lawsuit from Belcher Farmaceutica Ltda. claiming approximately 167 million Brazilian Reais (about 220 million RMB) for losses related to the cancellation of a vaccine registration agreement in Brazil[121]. - The company has engaged a professional legal team to respond to the lawsuit, believing the chances of Belcher's claims being supported by the Brazilian court are low[121]. Corporate Governance and Shareholder Matters - The company held its first extraordinary general meeting on February 21, 2024, where several proposals were approved, including amendments to the company's articles of association and the remuneration plans for the board of directors[87]. - The annual general meeting on June 27, 2024, approved the 2023 annual report and financial audit report, along with a proposal for profit distribution[88]. - The company did not distribute profits or increase capital reserves in the first half of 2024, indicating a focus on reinvestment or other strategic initiatives[92]. - The company has maintained a stable management structure with recent changes in board members, which may impact strategic direction moving forward[90]. - The company has not disclosed any updates on stock incentive plans or employee stock ownership plans, suggesting a potential focus on other forms of employee engagement[91]. - The company has proposed to increase or renew bank credit limits for 2024, indicating a strategy to enhance liquidity and financial flexibility[88]. Environmental Responsibility - The company invested 939,700 CNY in environmental protection during the reporting period[95]. - The company reduced carbon emissions by 8,194.9 tons through various carbon reduction measures[99]. - The company has established an environmental management system and has not faced any administrative penalties related to environmental issues during the reporting period[96]. - The company has implemented energy-saving measures, including optimizing cold storage operations and increasing the use of clean energy[98]. - The company’s long-term commitment to environmental responsibility has achieved compliance in wastewater and waste gas emissions[96]. Legal and Compliance - The company has not experienced any major litigation or arbitration matters during the reporting period[120]. - The company has confirmed that there are no issues regarding the integrity of the company or its controlling shareholders during the reporting period[119]. - The company has not issued any non-standard audit opinions for the previous annual report[119]. - The company has fully provided for impairment on loans to a related party, reflecting uncertainty in the recovery of these loans[123].

证券代码：688185 证券简称：康希诺 公告编号：2024-040 康希诺生物股份公司 第三届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 康希诺生物股份公司（以下简称"公司"）第三届监事会第四次会议于 2024 年 8 月 29 日在公司会议室以现场及通讯的方式召开，会议通知已于会议召开 10 日前以电子邮件形式送达全体监事。本次会议由监事会主席肖治召集，应到监事 3 人，实到监事 3 人。会议的召集、召开和表决程序符合《中华人民共和国公司 法》等法律法规及规范性文件和《康希诺生物股份公司章程》的规定，合法有效。 二、监事会会议审议情况 经与会监事审议，逐项表决，形成决议如下： 表决结果：同意 3 票，反对 0 票，弃权 0 票。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《2024 年半年度募集资金存放与实际使用情况专项报告》（公告编号：2024-041）。 （三）《关于使用暂时闲置募集资金进行现金管理的议案》 表决结果：同意 ...

证券代码：688185 证券简称：康希诺 公告编号：2024-039 康希诺生物股份公司 关于参加 2024 年度天津辖区上市公司半年报业绩说明会 暨投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2024 年 9 月 3 日（周二）15:00-16:30 会议召开方式：本次活动将采用网络远程的方式举行，投资者可以登录"全景 路演"（http://rs.p5w.net）参与本次互动交流。 一、会议类型 为进一步加强与投资者的互动交流，康希诺生物股份公司（以下简称"公司"） 将参加由天津证监局、天津上市公司协会与深圳市全景网络有限公司共同举办的 "2024 年度天津辖区上市公司半年报业绩说明会暨投资者网上集体接待日"活动。公 司将围绕 2024 年半年度经营情况等投资者所关心的问题，通过互动平台与投资者进 行沟通交流。 二、会议召开的时间、方式 1、召开时间：2024 年 9 月 3 日（周二）15:00-16:30。 2、召开方式：本次活动将采用网络远程的方式举 ...

董事會會議通告 康 希 諾 生 物 股 份 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2024年8月29日（星 期 四）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬公司截至2024年6月30日止六個月的中期業績及其發佈，以及建議派發中期股 息（如 有）。 承董事會命 康希諾生物股份公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 香港，2024年8月16日 於本通告日期，董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博士及王靖 女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建忠先生及 張耀樑先生。 Xuefeng YU 董事長 ...